irinotecan has been researched along with mln 8237 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L | 1 |
| Arcaroli, JJ; Bagby, SM; Bradshaw-Pierce, EL; Capasso, A; Davis, SL; Diamond, JR; Eckhardt, SG; Ecsedy, JA; Hyatt, SL; Klauck, PJ; McPhillips, K; Messersmith, WA; Pitts, TM; Purkey, A; Selby, HM; Spreafico, A; Tan, AC; Tentler, JJ | 1 |
| Anderson, CD; Burton, EC; Chakravarti, A; Chesnick, HM; King, PD; Lehman, NL; Li, X; McElroy, JP; Mifsud, CS; Sak, M; Usubalieva, A; Zumbar, CT | 1 |
| Arora, M; Christensen, S; Gandara, DR; Gong, IY; Kelly, K; Kim, EJ; Li, T; Riess, JW; Semrad, TJ | 1 |
2 trial(s) available for irinotecan and mln 8237
| Article | Year |
|---|---|
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azepines; Cohort Studies; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2021 |
2 other study(ies) available for irinotecan and mln 8237
| Article | Year |
|---|---|
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Azepines; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carboplatin; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Glioblastoma; Humans; Irinotecan; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2019 |